MedTrace Logo

A Study in Tanzania of a New Vaccine Against Two Types of Ebola

NCT05301504 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2023-02-08

No results posted yet for this study

Summary

An open label, first in human, non-randomised, dose escalation, single centre, phase Ib clinical trial

Conditions

  • Ebola

Interventions

BIOLOGICAL

ChAdOx1 biEBOV

ChAdOx1 biEBOV is provided as a liquid in glass vials and administered intramuscularly into the deltoid of the non-dominant arm (preferably)

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-30
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Tanzania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05301504 on ClinicalTrials.gov